245095-96-9Relevant academic research and scientific papers
Pyrazolo[1,5-a]pyrimidine with similar “amino-nitro-amino” arrangement characteristics to TATB: a novel heat-resistant explosive with fused structure
Yang, Feng,Xu, Yuangang,Wang, Pengcheng,Lin, Qiuhan,Bi, Fuqiang,Liu, Ning,Lu, Ming
, p. 2801 - 2808 (2021)
Exploring heat-resistant explosives that are easy to synthesize is a major challenge in the research of energetic materials. In this study, two novel fused-ring energetic compounds, namely 3,6-dinitropyrazolo[1,5-a]pyrimidine-5,7-diamine (4) and 5-amino-3,6-dinitropyrazolo[1,5-a]pyrimidin-7(4H)-one (5), were successfully preparedviaa simple synthetic method. In addition, their structure, thermal stability, mechanical sensitivity and detonation performance were fully explored. Noteworthily, compounds4and5both exhibit excellent thermal stability (TD(4) = 325 °C andTD(5) = 291 °C), particularly compound4, which features an “amino-nitro-amino” arrangement similar to that of TATB and exhibits a high density of 1.88 g cm?3and a greater thermal decomposition temperature than hexanitrostilbene (HNS, 316 °C). In addition, due to the aza-fused structure,4and5possess higher positive heats of formation (332.9 kJ mol?1and 181.4 kJ mol?1) than LLM-105 (11.0 kJ mol?1). These advanced features endow4and5with superior detonation performance (Vd(4) = 8338 m s?1andP(4) = 30.7 GPa;Vd(5) = 8097 m s?1andP(5) = 29.8 GPa) than TATB (Vd= 8179 m s?1andP= 30.5 GPa) and HNS (Vd= 7170 m s?1andP= 21.8 GPa). This study enriches prospects for the molecular design and crystal engineering of novel energetic materials with admirable molecular stability.
Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
-
Page/Page column 59, (2016/05/02)
The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:
Pyrazolopyrimidin CK2 and related heterocyclic compound as an inhibitor
-
Paragraph 0270, (2016/10/08)
The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:
FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
-
, (2013/03/26)
The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds
FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
-
, (2012/03/26)
This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example c
FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
-
, (2012/04/23)
This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases for example can
FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
-
, (2012/04/23)
This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example c
FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
-
, (2012/03/26)
This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example c
FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
-
, (2011/02/24)
The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.
